Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences has completed the first commercial sale of its ColoSTAT blood-based colorectal cancer test, marking the formal start of its clinical diagnostic testing operations. The test was ordered for a symptomatic patient, collected by partner 4Cyte Pathology, processed at Rhythm’s Parkville laboratory, and the result successfully reported to the clinician.
This initial case validates the full operational pathway from blood draw to result delivery in a routine clinical setting, confirming that ColoSTAT can be integrated into existing workflows as a scalable, revenue-generating service. With logistics and infrastructure proven, the company plans to immediately increase test volumes via direct engagement with primary care physicians and its ColoSTAT Access Program, which already has multiple sites onboarded in Victoria and New South Wales.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for accurate and early cancer detection. Founded in 2017 and headquartered in Melbourne, it aims to improve patient outcomes and reduce the global cancer burden, working with partners to commercialise and distribute its tests, including the ColoSTAT colorectal cancer assay.
Average Trading Volume: 1,060,816
Technical Sentiment Signal: Buy
Current Market Cap: A$67.63M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.